Dr Mark Toshner
Director of Translational Biomedical Research MPhil, University of Cambridge
About me
Dr Toshner is Director of the Heart Lung Research Institute Clinical Research Facility, where he works in cardiorespiratory therapy development. He is the Director of the Translational Biomedical Research MPhil and a practising clinician with a specialist interest in vascular diseases and COVID-19.
Mark is Director of the UniPHy Clinical Trials Network and co-chair of the PVRI (Pulmonary Vascular Research Institute) Innovative Drug Discovery Initiative Global Alliance, where he has embedded working groups in novel trial design, drug repurposing and equity of global access to medicines. He has also been Chief-Investigator, Co-Investigator or Sub-Investigator for 25 late phase clinical trials covering a spectrum of commercial and investigator-led studies, including four therapies which have achieved marketing authorisation and are in widespread clinical use.
His clinical trial experience includes as Joint Chief Investigator for HEAL-COVID, the world’s first decentralised therapeutic platform trial for the post-hospital phase of COVID-19, as the Cambridge PI for the Oxford/AstraZeneca vaccine phase 2/3 studies and he contributed to the local recruitment of patients for the COVID-19 practice-defining RECOVERY trial.
